(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 267.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Humacyte's revenue in 2026 is $2,016,000.On average, 7 Wall Street analysts forecast HUMA's revenue for 2026 to be $1,472,430,724, with the lowest HUMA revenue forecast at $957,346,394, and the highest HUMA revenue forecast at $1,965,313,144. On average, 7 Wall Street analysts forecast HUMA's revenue for 2027 to be $5,623,299,967, with the lowest HUMA revenue forecast at $2,393,365,984, and the highest HUMA revenue forecast at $10,447,997,203.
In 2028, HUMA is forecast to generate $25,081,498,631 in revenue, with the lowest revenue forecast at $11,140,030,763 and the highest revenue forecast at $44,013,067,970.